Altimmune (ALT) EV/EBIT: History & Chart

Altimmune, Inc.(ALT)

Biotechnology · Gaithersburg, MD

$2.670.00 (0.00%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Gaithersburg, MD

57 employees

altimmune.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jerome Benedict Durso

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Altimmune, Inc. (ALT)	$519.25M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$516.76M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$524.43M	N/A	N/A	N/A	N/A
Shattuck Labs, Inc. (STTK)vs ›	$529.58M	N/A	N/A	N/A	N/A
Nuvectis Pharma, Inc. (NVCT)vs ›	$531.52M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$531.98M	N/A	189.50x	189.50x	189.50x
908 Devices Inc. (MASS)vs ›	$505.87M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$533.04M	N/A	N/A	N/A	N/A
Crescent Biopharma, Inc. (CBIO)vs ›	$504.04M	N/A	N/A	N/A	N/A
Allogene Therapeutics, Inc. (ALLO)vs ›	$503.93M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Altimmune, Inc. (ALT)

$519.25M

N/A

Aclaris Therapeutics, Inc. (ACRS)vs ›

$516.76M

N/A

Immix Biopharma, Inc. (IMMX)vs ›

$524.43M